Tirzepatide protected mice from doxorubicin-induced heart damage and death by preventing the degradation of the antioxidant transcription factor Nrf2 through inhibition of the ER stress-related enzyme HRD1.
Protected heart function and improved survivalMice receiving tirzepatide alongside doxorubicin chemotherapy had preserved cardiac function, less heart tissue damage, and lower mortality — through a newly identified mechanism of protecting the antioxidant protein Nrf2 from destruction.
What the researchers found
Tirzepatide (daily subcutaneous injection for 14 days) protected C57BL/6 mice from doxorubicin-induced myocardial injury, cardiac dysfunction, and mortality. Tirzepatide significantly reduced oxidative stress and cardiomyocyte apoptosis both in vivo and in H9c2 cells. RNA sequencing and molecular analysis revealed the mechanism: doxorubicin triggers ER stress that upregulates HRD1, an E3 ubiquitin ligase that ubiquitinates and degrades Nrf2. Tirzepatide prevents ER stress-induced HRD1 upregulation, thereby preserving Nrf2 protein expression, nuclear translocation, and transcriptional activity — ultimately protecting cardiomyocytes from oxidative damage and death. Ad-Hrd1 overexpression and siNrf2 knockdown confirmed the mechanism.
Why it matters
Chemotherapy-related heart damage is a major cause of illness and death in cancer survivors, and no approved drug prevents it. Tirzepatide is already FDA-approved and widely available, making clinical translation potentially rapid. The newly identified HRD1-Nrf2 mechanism provides a specific molecular target and explains why tirzepatide has cardioprotective effects beyond its metabolic actions. This could change how oncologists protect their patients' hearts during treatment.
How the study worked
Male C57BL/6 mice received daily subcutaneous tirzepatide or vehicle for 14 days, with doxorubicin (15 mg/kg single IP injection) to induce cardiotoxicity. Echocardiography, histological assessment, and molecular analyses measured cardiac outcomes. In vitro studies used H9c2 cardiomyocyte cells. RNA sequencing of heart tissue identified potential targets. Mechanistic confirmation used adenoviral HRD1 overexpression (Ad-Hrd1) and Nrf2 siRNA knockdown to prove the HRD1-Nrf2 pathway.
What this study cannot tell us
Preclinical study in mice using a single high-dose doxorubicin model, which differs from the cumulative low-dose protocols used clinically. The 14-day treatment window is short relative to typical cancer treatment courses. Whether tirzepatide would interfere with doxorubicin's anti-tumor efficacy was not assessed — a critical concern for clinical translation. H9c2 cells are a rat cardiomyoblast line, not primary human cardiomyocytes. The GIP and GLP-1 receptor contributions were not individually dissected.
How to read the evidence
Published in Cardiovascular Research (a top cardiovascular journal), this is a well-designed preclinical study with thorough mechanistic validation using RNA sequencing, genetic overexpression, and knockdown experiments. However, it remains an animal study without human data or assessment of impact on anti-tumor efficacy.
When this study was published
Published in 2025, this is among the first studies to demonstrate tirzepatide's potential for chemotherapy cardioprotection, opening a completely new therapeutic area for this drug.
The bigger picture
Tirzepatide's potential applications continue to expand far beyond diabetes and obesity. This study adds chemotherapy cardioprotection to the growing list — alongside cardiovascular risk reduction, sleep apnea, kidney disease, and lipodystrophy. The HRD1-Nrf2 mechanism is particularly interesting because Nrf2 is the master regulator of antioxidant defense across many tissues, suggesting tirzepatide's protective effects may extend to other forms of oxidative injury beyond the heart.
Questions still open
- Does tirzepatide interfere with doxorubicin's anti-cancer effects, or can they be safely combined?
- Would tirzepatide protect against cardiotoxicity from other chemotherapy agents beyond doxorubicin?
- Can the HRD1-Nrf2 mechanism be targeted more directly with specific Nrf2 activators for patients who can't take tirzepatide?
Common questions
Can tirzepatide protect the heart during chemotherapy?
How does tirzepatide protect heart cells from chemotherapy damage?
Read the original research
Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.
Cardiovascular research, 121(12), 1865-1882
Citation
Yang, Dan; Chen, Yang-Hao; Chen, Yan-Kun; Zeng, Ya-Lin; Ling, Zhi-Yu. (2025). Tirzepatide alleviates doxorubicin-induced cardiotoxicity via inhibiting HRD1-mediated Nrf2 ubiquitination.. Cardiovascular research, 121(12), 1865-1882. https://doi.org/10.1093/cvr/cvaf033